AXLA

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Axcella Health (AXLA - Research Report), with a price target of $10.00. The company's shares closed last Friday at $2.33.According to TipRanks, LeBoyer is a 4-star analyst with an average return of 11.5% and a 33.83% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Ayala Pharmaceuticals, Tonix Pharma, and PDS Biotechnology.Currently, the analyst consensus on Axcella Health is a Strong Buy with an average price target of $8.50, representing a 264.81% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $8.
https://www.tipranks.com/news/blurbs/noble-financial-keeps-their-buy-rating-on-axcella-health-axla?utm_source=advfn.com&utm_medium=referral